Catalyst Funds Management Pty Ltd Purchases Shares of 47,175 Insmed, Inc. $INSM

Catalyst Funds Management Pty Ltd purchased a new stake in Insmed, Inc. (NASDAQ:INSM) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 47,175 shares of the biopharmaceutical company’s stock, valued at approximately $4,748,000. Insmed accounts for about 1.3% of Catalyst Funds Management Pty Ltd’s portfolio, making the stock its 10th largest position.

A number of other hedge funds have also recently made changes to their positions in the stock. Vanguard Group Inc. raised its position in Insmed by 0.3% in the first quarter. Vanguard Group Inc. now owns 18,268,122 shares of the biopharmaceutical company’s stock valued at $1,393,675,000 after purchasing an additional 49,149 shares during the period. Price T Rowe Associates Inc. MD grew its stake in shares of Insmed by 1.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 12,923,541 shares of the biopharmaceutical company’s stock valued at $985,938,000 after buying an additional 219,131 shares in the last quarter. Adage Capital Partners GP L.L.C. raised its holdings in shares of Insmed by 109.2% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 3,446,944 shares of the biopharmaceutical company’s stock valued at $262,967,000 after buying an additional 1,799,382 shares during the period. Artisan Partners Limited Partnership lifted its stake in Insmed by 3.0% during the 2nd quarter. Artisan Partners Limited Partnership now owns 3,314,341 shares of the biopharmaceutical company’s stock worth $333,555,000 after acquiring an additional 97,073 shares in the last quarter. Finally, Alliancebernstein L.P. lifted its stake in Insmed by 2.5% during the 1st quarter. Alliancebernstein L.P. now owns 2,423,513 shares of the biopharmaceutical company’s stock worth $184,890,000 after acquiring an additional 59,952 shares in the last quarter.

Insmed Stock Up 1.0%

INSM stock opened at $203.56 on Thursday. The company’s 50 day moving average price is $165.61 and its 200 day moving average price is $123.38. The firm has a market capitalization of $43.41 billion, a price-to-earnings ratio of -35.65 and a beta of 1.05. Insmed, Inc. has a fifty-two week low of $60.40 and a fifty-two week high of $205.11. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.33 and a current ratio of 6.68.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The firm had revenue of $142.34 million during the quarter, compared to analysts’ expectations of $114.33 million. During the same quarter in the prior year, the firm earned ($1.27) EPS. The firm’s revenue was up 52.4% compared to the same quarter last year. Insmed has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Insider Buying and Selling at Insmed

In other Insmed news, insider Orlov S. Nicole Schaeffer sold 30,000 shares of the firm’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $194.00, for a total value of $5,820,000.00. Following the sale, the insider directly owned 36,461 shares in the company, valued at $7,073,434. This trade represents a 45.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Melvin Md Sharoky sold 10,000 shares of Insmed stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $145.39, for a total value of $1,453,900.00. Following the sale, the director directly owned 262,675 shares of the company’s stock, valued at $38,190,318.25. This trade represents a 3.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 252,922 shares of company stock worth $43,533,383. 3.00% of the stock is currently owned by company insiders.

Analyst Ratings Changes

INSM has been the topic of a number of recent research reports. Jefferies Financial Group boosted their price target on shares of Insmed from $129.00 to $148.00 and gave the stock a “buy” rating in a research note on Wednesday, August 13th. Cowen restated a “buy” rating on shares of Insmed in a report on Thursday, October 30th. Cantor Fitzgerald assumed coverage on shares of Insmed in a research note on Tuesday, October 28th. They set an “overweight” rating and a $192.00 target price on the stock. Royal Bank Of Canada increased their target price on shares of Insmed from $139.00 to $215.00 and gave the stock an “outperform” rating in a report on Friday, October 31st. Finally, William Blair started coverage on shares of Insmed in a research note on Wednesday, August 20th. They issued an “outperform” rating for the company. Nineteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $173.29.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.